Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith

A method of treating a human or an animal, comprising:

• determining a presence of a neoplastic disease;
• orally, transdermally or transmucosally administering a regimen of effective doses of a pharmaceutically acceptable composition comprising at least one microcin methionine analogues or microcin methionine synthesis inhibitors, except for microcin 15m or a microcin from E. coli LP15, to the human or animal determines to have the presence of the neoplastic disease, over a sufficient time to achieve an effective treatment of the neoplastic disease.

Amended in its entirety to read:

• A pharmaceutical composition for oral, transdermal or transmucosal administration to a human or animal, comprising at least one pharmaceutically acceptable agent selected from the group consisting of a substantially purified microcin methionine analogue and a substantially purified tRNA microcin methioinine synthesis inhibitor, except for microcin 15m or a microcin from E. coli LP15, in unit dose form.